AU2005324794C1 - Somatostatin analogue formulations - Google Patents

Somatostatin analogue formulations Download PDF

Info

Publication number
AU2005324794C1
AU2005324794C1 AU2005324794A AU2005324794A AU2005324794C1 AU 2005324794 C1 AU2005324794 C1 AU 2005324794C1 AU 2005324794 A AU2005324794 A AU 2005324794A AU 2005324794 A AU2005324794 A AU 2005324794A AU 2005324794 C1 AU2005324794 C1 AU 2005324794C1
Authority
AU
Australia
Prior art keywords
administration
formulation
octreotide
injection
tumours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2005324794A
Other languages
English (en)
Other versions
AU2005324794B2 (en
AU2005324794A1 (en
Inventor
Fredrik Joabsson
Markus Johnsson
Andreas Norlin
Fredrik Tiberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Camurus AB
Original Assignee
Camurus AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0500807A external-priority patent/GB0500807D0/en
Priority claimed from GB0507811A external-priority patent/GB0507811D0/en
Priority claimed from PCT/GB2005/002217 external-priority patent/WO2005117830A1/fr
Priority claimed from GB0518878A external-priority patent/GB0518878D0/en
Application filed by Camurus AB filed Critical Camurus AB
Publication of AU2005324794A1 publication Critical patent/AU2005324794A1/en
Publication of AU2005324794B2 publication Critical patent/AU2005324794B2/en
Application granted granted Critical
Publication of AU2005324794C1 publication Critical patent/AU2005324794C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2005324794A 2003-11-07 2005-12-09 Somatostatin analogue formulations Active AU2005324794C1 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GB0326074.2 2003-11-07
GB0326075.9 2003-11-07
GB0412544.9 2004-06-04
GB0500807.3 2005-01-14
GB0500807A GB0500807D0 (en) 2005-01-14 2005-01-14 Formulation
GB0507811.8 2005-04-18
GB0507811A GB0507811D0 (en) 2005-04-18 2005-04-18 Formulation
PCT/GB2005/002217 WO2005117830A1 (fr) 2004-06-04 2005-06-06 Formulations de depot lipidique
AUPCT/GB2005/002217 2005-06-06
GB0518878A GB0518878D0 (en) 2005-09-15 2005-09-15 Formulations
GB0518878.4 2005-09-15
PCT/GB2005/004748 WO2006075124A1 (fr) 2005-01-14 2005-12-09 Formulations à base d'analogues de somatostatine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004696 Division WO2005046642A1 (fr) 2003-11-07 2004-11-05 Compositions de lipides et de peptides cationiques

Publications (3)

Publication Number Publication Date
AU2005324794A1 AU2005324794A1 (en) 2006-07-20
AU2005324794B2 AU2005324794B2 (en) 2010-05-13
AU2005324794C1 true AU2005324794C1 (en) 2010-12-02

Family

ID=35986077

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005324794A Active AU2005324794C1 (en) 2003-11-07 2005-12-09 Somatostatin analogue formulations

Country Status (7)

Country Link
EP (1) EP1843746B1 (fr)
JP (1) JP5171262B2 (fr)
KR (1) KR100983746B1 (fr)
AU (1) AU2005324794C1 (fr)
CA (1) CA2594711C (fr)
PL (1) PL1843746T3 (fr)
WO (1) WO2006075124A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
DE602005026998D1 (de) 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
ES2343641T3 (es) 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
EP1843751B1 (fr) 2005-01-21 2020-09-30 Camurus Ab Compositions lipidiques pharmaceutiques
DK1888031T3 (da) 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
AU2015227534B2 (en) * 2007-06-15 2017-02-23 Camurus Ab Peptide slow-release formulations
AU2012202338B2 (en) * 2007-06-15 2015-07-09 Camurus Ab Peptide slow-release formulations
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
EP2052716B1 (fr) * 2007-10-24 2014-12-31 Camurus AB Formulations à libération contrôlée
KR100998175B1 (ko) 2008-05-30 2010-12-03 애니젠 주식회사 소마토스타틴의 제조방법
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
CA2755436C (fr) 2009-03-19 2019-10-29 Claude Carelli Peptides destines a inhiber l'igf-1
TWI624271B (zh) * 2011-05-25 2018-05-21 凱慕路斯公司 包含低黏度混合物之預調配物及其形成方法，及該低黏度混合物或預調配物之用途
KR101494594B1 (ko) * 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
BR112014013693B1 (pt) * 2011-12-05 2023-01-31 Camurus Ab Pré-formulação, e, uso de uma pré-formulação
TW201336526A (zh) * 2012-01-31 2013-09-16 參天製藥股份有限公司 非水性液體組成物
MX350964B (es) * 2012-05-25 2017-09-27 Camurus Ab Formulaciones de agonistas del receptor de somatostatina.
KR101586790B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EP2823808A1 (fr) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Composition pharmaceutique de lanréotide à libération prolongée
CN109789215B (zh) 2016-09-27 2022-12-16 卡姆拉斯公司 含有生长激素抑制素受体激动剂的制剂
EP3421485A1 (fr) 2017-06-30 2019-01-02 Université de Strasbourg Anticorps pour la prévention et le traitement de la thrombose
EP3437651A1 (fr) 2017-08-03 2019-02-06 Université de Strasbourg Peptides pour le traitement et la prévention de la stéatose hépatique non alcoolique
IL275188B2 (en) 2017-12-14 2024-03-01 Univ Strasbourg Use of cyclic tripeptide to improve cellular energy metabolism
IL284029B2 (en) 2018-12-21 2023-09-01 Univ Strasbourg Peptides for the treatment and prevention of diabetes and related disorders
JP2021059680A (ja) * 2019-10-08 2021-04-15 花王株式会社 液晶組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807573A (en) * 1994-06-15 1998-09-15 Gs Development Ab Lipid based composition containing diacylglycerol, phospholipid, polar liquid and biologically active material

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0643620B1 (fr) * 1991-10-04 1999-07-21 Gs Development Ab Particules, procede de preparation desdites particules et utilisations
WO1993006921A1 (fr) * 1991-10-04 1993-04-15 Gs Biochem Ab Particules, procede de preparation desdites particules et utilisations
CA2231273A1 (fr) * 1995-10-12 1997-04-17 Lise Sylvest Nielsen Composition pharmaceutique pour l'administration d'un principe actif sur ou au travers d'une surface cutanee ou muqueuse
CA2286052A1 (fr) * 1997-04-17 1998-10-29 Lise Sylvest Nielsen Nouveau systeme bioadhesif d'administration de medicaments base sur des cristaux liquides
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
WO2005046642A1 (fr) * 2003-11-07 2005-05-26 Camurus Ab Compositions de lipides et de peptides cationiques
US8182834B2 (en) * 2004-01-23 2012-05-22 Camurus Ab Ternary non-lamellar lipid compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807573A (en) * 1994-06-15 1998-09-15 Gs Development Ab Lipid based composition containing diacylglycerol, phospholipid, polar liquid and biologically active material

Also Published As

Publication number Publication date
CA2594711C (fr) 2012-11-06
WO2006075124A1 (fr) 2006-07-20
AU2005324794B2 (en) 2010-05-13
PL1843746T3 (pl) 2011-09-30
JP5171262B2 (ja) 2013-03-27
EP1843746B1 (fr) 2011-03-16
AU2005324794A1 (en) 2006-07-20
KR20070104599A (ko) 2007-10-26
JP2008526933A (ja) 2008-07-24
EP1843746A1 (fr) 2007-10-17
CA2594711A1 (fr) 2006-07-20
KR100983746B1 (ko) 2010-09-24

Similar Documents

Publication Publication Date Title
AU2005324794C1 (en) Somatostatin analogue formulations
US20210268112A1 (en) Peptide slow-release formulations
US8871712B2 (en) Somatostatin analogue formulations
EP1888031B1 (fr) Formulations d'analogues de glp-1
JP6081479B2 (ja) 頑強な徐放性ペプチド製剤
JP6265888B2 (ja) 制御放出ペプチド製剤
WO2009024795A1 (fr) Formulations lipidiques à teneur en acide
AU2015227534B2 (en) Peptide slow-release formulations
AU2012202338B2 (en) Peptide slow-release formulations
ES2363419T3 (es) Formulaciones de análogos de somatostatina.

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD PRIORITY DETAILS UNDER INID (62) WO2005/046642

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 JUN 2010.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 JUN AND 22 JUL 2010

FGA Letters patent sealed or granted (standard patent)